On Wednesday, May 30, 2018, the President signed into law:
S. 204, the “Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017,” which authorizes certain patients to seek access to certain unapproved investigational drugs directly from a drug sponsor or manufacturer; limits the use of clinical outcomes and liability arising from the provision of such drugs; and provides reporting requirements for the use and outcomes of the new authority.
